- Report
- October 2026
- 160 Pages
Global
From €3082EUR$3,320USD£2,571GBP
€3852EUR$4,150USD£3,213GBP
- Report
- August 2026
- 160 Pages
Global
From €3082EUR$3,320USD£2,571GBP
€3852EUR$4,150USD£3,213GBP
- Report
- July 2026
- 160 Pages
Global
From €3082EUR$3,320USD£2,571GBP
€3852EUR$4,150USD£3,213GBP
- Report
- July 2026
- 160 Pages
Global
From €3082EUR$3,320USD£2,571GBP
€3852EUR$4,150USD£3,213GBP
- Report
- January 2026
- 160 Pages
Global
From €2933EUR$3,160USD£2,447GBP
€3666EUR$3,950USD£3,058GBP
- Report
- May 2026
- 150 Pages
United States
From €4502EUR$4,850USD£3,755GBP
- Report
- January 2025
- 153 Pages
Global
From €5523EUR$5,950USD£4,607GBP
- Report
- October 2024
- 200 Pages
Global
From €3481EUR$3,750USD£2,903GBP
- Report
- February 2025
- 153 Pages
Global
From €5523EUR$5,950USD£4,607GBP
- Report
- May 2024
- 200 Pages
Global
From €3852EUR$4,150USD£3,213GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2785EUR$3,000USD£2,323GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1160EUR$1,250USD£968GBP
- Report
- September 2022
- 30 Pages
Global
From €2553EUR$2,750USD£2,129GBP
- Report
- May 2026
- 200 Pages
South Korea
From €2589EUR$2,789USD£2,159GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2589EUR$2,789USD£2,159GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2589EUR$2,789USD£2,159GBP
- Report
- June 2025
- 400 Pages
Global
From €4594EUR$4,949USD£3,832GBP
- Report
- June 2025
- 250 Pages
United States
From €2589EUR$2,789USD£2,159GBP
- Report
- June 2025
- 300 Pages
Europe
From €3591EUR$3,869USD£2,996GBP
- Report
- May 2025
- 300 Pages
Global
From €4594EUR$4,949USD£3,832GBP

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes.
Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain.
Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more